HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cholinergic nervous system and glaucoma: From basic science to clinical applications.

Abstract
The cholinergic system has a crucial role to play in visual function. Although cholinergic drugs have been a focus of attention as glaucoma medications for reducing eye pressure, little is known about the potential modality for neuronal survival and/or enhancement in visual impairments. Citicoline, a naturally occurring compound and FDA approved dietary supplement, is a nootropic agent that is recently demonstrated to be effective in ameliorating ischemic stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, cerebrovascular diseases, memory disorders and attention-deficit/hyperactivity disorder in both humans and animal models. The mechanisms of its action appear to be multifarious including (i) preservation of cardiolipin, sphingomyelin, and arachidonic acid contents of phosphatidylcholine and phosphatidylethanolamine, (ii) restoration of phosphatidylcholine, (iii) stimulation of glutathione synthesis, (iv) lowering glutamate concentrations and preventing glutamate excitotoxicity, (v) rescuing mitochondrial function thereby preventing oxidative damage and onset of neuronal apoptosis, (vi) synthesis of myelin leading to improvement in neuronal membrane integrity, (vii) improving acetylcholine synthesis and thereby reducing the effects of mental stress and (viii) preventing endothelial dysfunction. Such effects have vouched for citicoline as a neuroprotective, neurorestorative and neuroregenerative agent. Retinal ganglion cells are neurons with long myelinated axons which provide a strong rationale for citicoline use in visual pathway disorders. Since glaucoma is a form of neurodegeneration involving retinal ganglion cells, citicoline may help ameliorate glaucomatous damages in multiple facets. Additionally, trans-synaptic degeneration has been identified in humans and experimental models of glaucoma suggesting the cholinergic system as a new brain target for glaucoma management and therapy.
AuthorsMuneeb A Faiq, Gadi Wollstein, Joel S Schuman, Kevin C Chan
JournalProgress in retinal and eye research (Prog Retin Eye Res) Vol. 72 Pg. 100767 (09 2019) ISSN: 1873-1635 [Electronic] England
PMID31242454 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2019 Elsevier Ltd. All rights reserved.
Chemical References
  • Cholinergic Agents
  • Neuroprotective Agents
  • Cytidine Diphosphate Choline
  • Choline
  • Acetylcholine
Topics
  • Acetylcholine (physiology)
  • Choline (physiology)
  • Cholinergic Agents (pharmacokinetics, therapeutic use)
  • Cytidine Diphosphate Choline (metabolism)
  • Glaucoma (drug therapy, metabolism, physiopathology)
  • Humans
  • Neuroprotective Agents (pharmacokinetics, therapeutic use)
  • Retinal Ganglion Cells (physiology)
  • Signal Transduction (physiology)
  • Visual Cortex (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: